Biologics in Severe Asthma: Optimizing Therapeutic Selection and Patient Outcomes

To participate in this activity, please:

Welcome to this audiovisual activity on the pathophysiologic basis and use of biologic therapy for the treatment of patients with severe asthma. This case-based activity focuses on considerations, including phenotypes and biomarkers, in individualizing treatment with the 5 monoclonal antibodies currently approved for severe asthma in the United States. The role of shared decision-making is discussed as an approach to individualizing therapy and improving patient outcomes. Clinical criteria for assessing treatment response to biologic therapy and how to modify therapy when needed are also discussed.

Course Credit:

0.75 AMA PRA Category 1 CreditsTM


Opens: 2020-12-14
Closes: 2021-12-14

Target Audience:

This activity was developed for pulmonologists, allergists, immunologists, primary care physicians, and other healthcare professionals involved in the care of patients with severe asthma.

This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

    Presenting Faculty

  • Reynold A. Panettieri, Jr, MD

    Vice Chancellor, Translational Medicine and Science
    Director, Rutgers Institute for Translational Medicine and Science
    Professor of Medicine, Rutgers University
    New Brunswick, New Jersey
    Emeritus Professor of Medicine, University of Pennsylvania